Home » Blog » HCA to Use Genomic Patient EHR Info to Recommend Targeted Therapies and ASCO Recommendations for Survivorship Care Plans

HCA to Use Genomic Patient EHR Info to Recommend Targeted Therapies and ASCO Recommendations for Survivorship Care Plans

IP Blog | Dave Melin | February 1, 2015

BioBlog Weekly oncologyThis week in healthcare, Hospital Corporation of America embarks on a widespread molecular profiling plan, and ASCO releases recommendations about survivorship care plans, Medicaid reform, and chemotherapy-induced peripheral neuropathy.

Putting Precision Medicine For Cancer At Work In America’s Largest Hospital

“In one of the largest initiatives of its kind, the for-profit hospital chain Hospital Corporation of America (HCA) has embarked on a plan to molecularly profile the tumor of over 100,000 cancer patients, marry the genomic information to clinical data from a patient’s electronic health record, and recommend targeted therapies.”

Treatment Summaries and Survivorship Care Plans: The Approach by the Commission on Cancer to Increase Use

In this article, the authors examine treatment summaries and survivorship care plans — particularly the ones developed by ASCO — and the factors behind why their uptake by hospital has been slower than desired.

Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary

This Journal of Clinical Oncology report chronicles ASCO’s expert panel recommendations surrounding the prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN).

American Society of Clinical Oncology Policy Statement on Medicaid Reform

In this Journal of Clinical Oncology article, ASCO sets forth its policy statement surrounding impending Medicaid reform. Among its recommendations: expanding Medicaid coverage in all 50 states, requiring coverage for genetic testing for patients that meet guideline criteria, and equalizing physician payment rates between Medicaid and Medicare.

FDA and Social Media: Impact on Prescription Drug Advertising

This post, by the “Pharmageek”, digs into the issues surrounding direct-to-consumer drug advertising by pharmaceutical companies via social media, especially on Twitter. This has gained enough steam that last year the FDA even proposed regulations for companies’ mentions of products on Twitter. The question to ponder: “Should all our tweets be regulated as potential advertisement for whichever product is mentioned?”

Want more health care landscape updates and insights? Follow us on Twitter @innovpartners.

Topics in this Post:

Leave a Comment

Your email address will not be published. Required fields are marked *